Skip to content

Pennsylvania Medicaid

Does Pennsylvania Medicaid cover Wegovy?

No. Pennsylvania Medicaid's policies on file exclude Wegovy for weight loss on Medicaid plans.

Policy document

  • Medicaid: Not covered. Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of o...

Earliest policy review June 4, 2026. How we verify · Check your exact plan · Medicaid card names in Pennsylvania

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Medicaid plans.

Not covered

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The bulletin states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Wegovy is non-preferred on the PDL; for non-diabetes indications it requires step through preferred agents. This entry covers the weight loss exclusion only.

Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial approval — Wegovy for CV risk reduction (non-preferred)

All of:

  • Prescribed by or in consultation with an appropriate specialist (e.g., cardiologist, vascular surgeon, neurologist)
  • Recent BMI ≥ 27 kg/m2
  • Used in combination with optimized pharmacotherapy for established CVD per current consensus guidelines unless contraindicated or not tolerated
  • Used in combination with lifestyle changes and behavioral modifications
  • Age-appropriate per FDA labeling, compendia, or peer-reviewed literature
  • No contraindication to the prescribed drug
  • History of therapeutic failure of, OR contraindication to, OR intolerance to the maximum FDA-approved dose of Ozempic (semaglutide) — OR for Wegovy 2.4 mg: dose titration to semaglutide 2 mg completed plus medical reason for 2.4 mg dose

Plus any one of:

  • Prior myocardial infarction
  • Prior stroke
  • Peripheral arterial disease with: intermittent claudication with ankle-brachial index < 0.85 at rest, OR history of peripheral arterial revascularization, OR history of amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of specialist prescribing or consultation (cardiologist, vascular surgeon, or neurologist)
  • Recent BMI documentation (≥ 27 kg/m2)
  • Documentation of qualifying CV event: prior MI, prior stroke, or PAD with claudication (ABI <0.85), revascularization history, or amputation due to atherosclerotic disease
  • Documentation of current optimized pharmacotherapy for CVD per consensus guidelines, or reason it is contraindicated/not tolerated
  • Documentation of therapeutic failure of Ozempic (semaglutide) at maximum FDA-approved dose, OR contraindication or intolerance to Ozempic (with chart documentation of troubleshooting attempts over at least 1 month if intolerance-based)
  • For Wegovy 2.4 mg: documentation that dose titration to semaglutide 2 mg has been completed and medical reason supporting need for 2.4 mg dose — OR documentation of therapeutic failure of Ozempic at maximum dose
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to the prescribed drug
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use supported by literature/guidelines

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Renewal requires: (1) prescribed by or in consultation with appropriate specialist (cardiologist, vascular surgeon, neurologist); (2) used in combination with optimized pharmacotherapy for established CVD per current consensus guidelines unless contraindicated or not tolerated; (3) continued lifestyle changes and behavioral modifications; (4) no contraindication; (5) step-therapy requirement maintained (therapeutic failure/contraindication/intolerance to Ozempic max dose). BMI and qualifying CV event documentation not explicitly re-verified at renewal per renewal guidelines as stated, but specialist and GDMT requirements are re-checked.

Not covered when

  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: Wegovy is non-preferred for all non-diabetes indications. For CV risk reduction, the step-therapy requirement is therapeutic failure of/contraindication to/intolerance to the maximum FDA-approved dose of Ozempic (semaglutide). PAD qualifying criteria are specific: requires at least one of intermittent claudication with ABI <0.85 at rest, history of peripheral arterial revascularization, or amputation due to atherosclerotic disease. For Wegovy 2.4 mg strength specifically, an alternative pathway exists: prior therapeutic failure of Ozempic at max dose OR (completed titration to semaglutide 2 mg plus medical reason for 2.4 mg). All non-OSA/non-MASH non-diabetes indications require a recent 6-month trial of lifestyle changes and behavioral modifications OR medical reason why immediate treatment is necessary at initial request. For CV and MASH, lifestyle changes are required but the 6-month prior trial requirement does not apply — concurrent lifestyle modification suffices. Prescriptions limited to 1-month supply per fill. Approval duration up to 6 months for non-diabetes, non-OSA indications.

Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial approval — Wegovy for MASH (non-preferred)

All of:

  • Prescribed by or in consultation with a hepatologist or gastroenterologist
  • Diagnosis of MASH with moderate to advanced liver fibrosis (stage F2 or F3) confirmed by approved method
  • No significant alcohol use (defined as >1 drink/day for natal females or >2 drinks/day for natal males) and no alcohol dependence
  • Used in combination with optimized pharmacotherapy for established comorbid diseases (CVD, dyslipidemia, diabetes, hypertension) per current consensus guidelines unless contraindicated or not tolerated
  • Used in combination with lifestyle changes and behavioral modifications
  • Age-appropriate per FDA labeling, compendia, or peer-reviewed literature
  • No contraindication to the prescribed drug
  • History of therapeutic failure of, OR contraindication to, OR intolerance to the maximum FDA-approved dose of Ozempic (semaglutide)

Plus any one of:

  • Liver biopsy within the past 3 years confirming F2-F3 fibrosis
  • FIB-4 index ≥ 1.3 (age <65) or ≥ 2.0 (age ≥65) PLUS one of: liver stiffness by VCTE (FibroScan), MRE, shear wave elastography (SWE), or Enhanced Liver Fibrosis (ELF) score

Initial approval — Wegovy 2.4 mg for MASH (non-preferred, strength-specific)

All of:

  • All standard MASH criteria above met

Plus any one of:

  • Dose titration to semaglutide 2 mg completed AND medical reason supporting need for 2.4 mg dose
  • History of therapeutic failure of Ozempic (semaglutide) at maximum FDA-approved dose

Initial approval — addition of Wegovy to Rezdiffra (resmetirom) for MASH

All of:

  • All standard MASH criteria above met
  • Failed to show improvement in liver fibrosis after ≥ 12 months of Rezdiffra (resmetirom)

Documentation to bring

  • Documentation of specialist prescribing or consultation (hepatologist or gastroenterologist)
  • Documentation of MASH diagnosis with F2-F3 fibrosis: liver biopsy within past 3 years OR FIB-4 ≥ 1.3 (<65 yrs) or ≥ 2.0 (≥65 yrs) plus VCTE/MRE/SWE/ELF result
  • Documentation of no significant alcohol use (≤1 drink/day natal female; ≤2 drinks/day natal male) and no alcohol dependence
  • Documentation of optimized pharmacotherapy for comorbid diseases or reason contraindicated/not tolerated
  • Documentation of therapeutic failure of Ozempic at maximum FDA-approved dose, OR contraindication or intolerance to Ozempic (with chart documentation of troubleshooting attempts over at least 1 month if intolerance-based)
  • For Wegovy 2.4 mg: documentation that dose titration to semaglutide 2 mg has been completed and medical reason for 2.4 mg dose — OR therapeutic failure of Ozempic at max dose
  • If currently on Rezdiffra (resmetirom): documentation of failure to improve liver fibrosis after ≥ 12 months of Rezdiffra
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to the prescribed drug
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Renewal requires: (1) prescribed by or in consultation with hepatologist or gastroenterologist; (2) no significant alcohol use; (3) optimized pharmacotherapy for comorbid diseases; (4) continued lifestyle changes and behavioral modifications; (5) step-therapy requirement (therapeutic failure/contraindication/intolerance to Ozempic max dose). If on GLP-1 for ≥ 1 year, must document: resolution of steatohepatitis and improvement or no worsening of liver fibrosis, OR improvement of liver fibrosis and no worsening of steatohepatitis. If currently taking Rezdiffra (resmetirom) and adding GLP-1: must have failed to show improvement in liver fibrosis after ≥ 12 months of Rezdiffra. Baseline fibrosis staging not re-confirmed at renewal per renewal guidelines.

Not covered when

  • Cirrhotic MASH excluded (noncirrhotic MASH only)
  • Significant alcohol use (>1 drink/day natal female or >2 drinks/day natal male) or alcohol dependence is an exclusion
  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: MASH fibrosis confirmation: liver biopsy must be within past 3 years (36 months). For FIB-4 pathway, FIB-4 cutoff is age-stratified: ≥1.3 for patients <65 years old, ≥2.0 for patients ≥65 years old. Second-line imaging/test required alongside FIB-4: VCTE (FibroScan), MRE, SWE, or ELF score. Alcohol limits are stated in drinks per day, not grams (policy does not specify gram equivalents). Concomitant Rezdiffra requires prior 12-month trial failure of resmetirom before adding GLP-1. At renewal, if on GLP-1 for ≥1 year, must document liver fibrosis/steatohepatitis response. All non-OSA/non-MASH/non-CV non-diabetes indications require 6-month prior lifestyle trial; MASH requires only concurrent lifestyle modification. Approval up to 6 months per cycle. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Pennsylvania Medicaid has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does Pennsylvania Medicaid cover Wegovy?
No. Pennsylvania Medicaid's policies on file exclude Wegovy for weight loss on Medicaid plans.
How long does a Wegovy approval last with Pennsylvania Medicaid?
Heart Disease Risk Reduction — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months. Liver Disease (MASH) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.
What does Pennsylvania Medicaid require to renew Wegovy?
Heart Disease Risk Reduction — Applies to Medicaid plans. Renewal requires: (1) prescribed by or in consultation with appropriate specialist (cardiologist, vascular surgeon, neurologist); (2) used in combination with optimized pharmacotherapy for established CVD per current consensus guidelines unless contraindicated or not tolerated; (3) continued lifestyle changes and behavioral modifications; (4) no contraindication; (5) step-therapy requirement maintained (therapeutic failure/contraindication/intolerance to Ozempic max dose). BMI and qualifying CV event documentation not explicitly re-verified at renewal per renewal guidelines as stated, but specialist and GDMT requirements are re-checked. Liver Disease (MASH) — Applies to Medicaid plans. Renewal requires: (1) prescribed by or in consultation with hepatologist or gastroenterologist; (2) no significant alcohol use; (3) optimized pharmacotherapy for comorbid diseases; (4) continued lifestyle changes and behavioral modifications; (5) step-therapy requirement (therapeutic failure/contraindication/intolerance to Ozempic max dose). If on GLP-1 for ≥ 1 year, must document: resolution of steatohepatitis and improvement or no worsening of liver fibrosis, OR improvement of liver fibrosis and no worsening of steatohepatitis. If currently taking Rezdiffra (resmetirom) and adding GLP-1: must have failed to show improvement in liver fibrosis after ≥ 12 months of Rezdiffra. Baseline fibrosis staging not re-confirmed at renewal per renewal guidelines.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Card and program names on file in Pennsylvania

These names map to Pennsylvania Medicaid, including older names and spelling variants. This is not a list of plans currently accepting members.

Also under Pennsylvania Medicaid: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Capital BlueCross, Highmark, Independence Blue Cross, Alabama Medicaid, California Medicaid, Clover Health, Colorado Medicaid, Connecticut Medicaid

All insurance plans · All medications

Summary of Pennsylvania Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.